The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
B‐cell targeted therapies in human autoimmune diseases: an updated perspective
Abstract
Summary: The advent of therapies that specifically target the B‐lymphocyte lineage in human disease has rejuvenated interest in the mechanistic biology by which B cells mediate autoimmunity. B cells have a multitude of effector functions including production of self‐reactive antibodies, ability to present antigen to T lymphocytes in the context of costimulation, involvement in generation and maintenance of neo‐organogenesis at sites of disease, and opposing function through production of both immunostimulatory and immunomodulatory cytokines. In this review, we first discuss the role of B cells in driving autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, and Sjögren’s syndrome, and discuss how studies in these diseases have revealed differentially important roles for the multiple B‐cell effector functions. These data reveal the complex and interrelated roles of B cells working in concert with other components of the innate and adaptive immune system to drive pathogenesis. We then focus on data from mouse and human in which B cells in the setting of disease have been targeted with drugs directed against CD20, CD22, and the BAFF (B‐cell activating factor belonging to the tumor necrosis factor family)/APRIL (a proliferation inducing ligand) pathways. Pre‐clinical studies in animal models in addition to and clinical trials targeting B cells have added further to the understanding of the differential roles B cells play in disease both through demonstration of clinical efficacy in the context of B‐cell depletion or modulation, and also by failure of B‐cell targeting in some diseases and disease patient subgroups. Moving forward, it will be imperative to apply these lessons to new interventional trials to ensure better targeting of the B‐cell lineage and concomitantly better selection of patients most likely to benefit from these therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 2×
“Binding of rituximab to CD20 on target cells allows for both complement and FccR-mediated cell killing in addition to reported modulation of apoptotic pathways rendering cells more sensitive to chemotherapeutic agents (14, 65, 66).”
BackgroundEfficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
Bingham, C. O., Looney, R. J., Deodhar, A., Halsey, N., Greenwald, M., Codding, C., Trzaskoma, B., Martin, F., Agarwal, S., & Kelman, A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25034 · Cited by 459
van Assen, S., Holvast, A., Benne, C. A., Posthumus, M. D., van Leeuwen, M. A., Voskuyl, A. E., Blom, M., Risselada, A. P., de Haan, A., Westra, J., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25033 · Cited by 371 · cited 1×
“In contrast to assessing the effects of immunization administered immediately before the initiation of B cell depletion, a second study addressed the effectiveness of early (4–8 weeks) versus late (6–10 months) immunization with trivalent influenza vaccine after patients were treated with rituximab (145).”
BackgroundCarnahan, J., Stein, R., Qu, Z., Hess, K., Cesano, A., Hansen, H. J., & Goldenberg, D. M. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.05.007 · Cited by 175
Cited by
B Cell Responses: Cell Interaction Dynamics and Decisions
Cyster, J. G., & Allen, C. D. C. (2019) · Cell · doi:10.1016/j.cell.2019.03.016 · Cited by 971
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to Humans
Libby, P., Lichtman, A. H., & Hansson, G. K. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.009 · Cited by 671
Kyaw, T., Tay, C., Krishnamurthi, S., Kanellakis, P., Agrotis, A., Tipping, P., Bobik, A., & Toh, B.-H. (2011) · Circulation Research · doi:10.1161/circresaha.111.248542 · Cited by 333
Sage, P. T., & Sharpe, A. H. (2016) · Immunological Reviews · doi:10.1111/imr.12411 · Cited by 330
Metadata
- Authors
- Townsend, M. J., Monroe, J. G., & Chan, A. C.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2010-08-19
- Volume
- 237
- Issue
- 1
- Pages
- 264-283
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W1946521533
- Cited by
- 232
- References
- 8
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: B‐cell targeted therapies in human autoimmune diseases: an updated perspective. https://app.cochat.ai/papers/10.1111/j.1600-065x.2010.00945.x
- The paper
- Townsend, M. J., Monroe, J. G., & Chan, A. C. (2010). B‐cell targeted therapies in human autoimmune diseases: an updated perspective. Immunological Reviews. https://doi.org/10.1111/j.1600-065x.2010.00945.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.